Publicacions en col·laboració amb investigadors/es de Instituto de Investigación Sanitaria de Navarra (35)

2024

  1. DNA electroporation in a vacuum: A “shocking” innovation for vaccines

    Molecular Therapy Nucleic Acids

  2. Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice

    Acta Pharmacologica Sinica

2023

  1. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies

    Frontiers in Immunology, Vol. 13

  2. Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies(Front. Immunol., (2023), 13, (1044025), 10.3389/fimmu.2022.1044025)

    Frontiers in Immunology

  3. FOXP3 expression diversifies the metabolic capacity and enhances the efficacy of CD8 T cells in adoptive immunotherapy of melanoma

    Molecular Therapy, Vol. 31, Núm. 1, pp. 48-65

  4. Mutated trimeric RBD vaccines: a platform against variants of concern

    Signal Transduction and Targeted Therapy

  5. PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells

    Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526

  6. Targeting FOXP3 Tumor-Intrinsic Effects Using Adenoviral Vectors in Experimental Breast Cancer

    Viruses, Vol. 15, Núm. 9

2022

  1. CAR-T Cells for the Treatment of Lung Cancer

    Life, Vol. 12, Núm. 4

  2. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

    Frontiers in Immunology, Vol. 13

  3. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

  4. Impact of tumor microenvironment on adoptive T cell transfer activity

    International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 1-31

  5. Intratumoral electroporation of a self-amplifying RNA expressing IL-12 induces antitumor effects in mouse models of cancer

    Molecular Therapy - Nucleic Acids, Vol. 29, pp. 387-399

  6. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

2021

  1. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model

    Journal of Nanobiotechnology, Vol. 19, Núm. 1

  2. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 11

  3. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

  4. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

  5. The tgf-β pathway: A pharmacological target in hepatocellular carcinoma?

    Cancers, Vol. 13, Núm. 13

2020

  1. Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-18